<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Purpose: Bacopa monnieri (L.) WETTST. is extensively used in traditional Indian medicine as a nerve tonic </plain></SENT>
<SENT sid="1" pm="."><plain>The neuropharmacological properties of bacopaside I, an important component from B. monnieri, have not been studied so far </plain></SENT>
<SENT sid="2" pm="."><plain>The present study investigated the effects and possible mechanisms of bacopaside I in a rat model of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>Methods: Adult male Sprague-Dawley rats were divided into five groups: sham-operated group, <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> group, and three bacopaside I-treated groups (3, 10 and 30 mg/kg) respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Bacopaside I or vehicle (0.5% CMC-Na) was administered orally once a day for 6 days </plain></SENT>
<SENT sid="5" pm="."><plain>On the third day, the rats were subjected to 2 h right MCAO via the intraluminal filament technique and 70 h reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>Assessment of behavioral deficits both at 22 and 70 h, and measurement of cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:hpo ids='HP_0000969'>edema</z:hpo>, cerebral energy metabolism, relative enzyme activities, malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>) content, nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) level, and <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzyme activities at 70 h, performed after MCAO reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>Results: Bacopaside I (10 and 30 mg/kg) treatment produced significant reduction in neurological deficits at 22 and 70 h, and significantly reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and <z:hpo ids='HP_0000969'>edema</z:hpo> at 70 h, when compared with the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> group </plain></SENT>
<SENT sid="8" pm="."><plain>Animal, that were orally treated with bacopaside I (3, 10 and 30 mg/kg) showed increased the brain ATP content, energy charge (EC), total <z:chebi fb="1" ids="16708">adenine</z:chebi> <z:chebi fb="9" ids="36976">nucleotides</z:chebi> (TAN), nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) level, Na+K+ATPase and Ca2+Mg2+ATPase activity </plain></SENT>
<SENT sid="9" pm="."><plain>Bacopaside I (3, 10 and 30 mg/kg) treatment also improved <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzyme activities including brain <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD), catalase (CAT), <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase (GSH-Px), in varying degrees, compared with the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> group </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, three doses of bacopaside I (3, 10 and 30 mg/kg) markedly inhibited the increase in <z:chebi fb="14" ids="32506">MDA</z:chebi> content of the brain </plain></SENT>
<SENT sid="11" pm="."><plain>Conclusions: These findings indicated that bacopaside I possess a neuroprotective effect against injury caused by <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The protective mechanism might be related to improving cerebral energy metabolism and increasing <z:chebi fb="11" ids="22586">antioxidant</z:chebi> levels </plain></SENT>
</text></document>